Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium

Completed · Phase 1

Conditions studied: Adverse Events, Pharmacokinetic

In brief

To evaluate safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.

Key facts

Study ID

NCT00681395

Run by

AstraZeneca

People needed

64

Starts

2008-05-01

Last updated by the study team

2012-09-28

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• General good health
• BMI 19 to 29

You may not qualify if…

• Currently enrolled in another study
• Females who are pregnant or breastfeeding

Where it is running

• Site Reference ID/Investigator# 8089 — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.